Skip to main content

$0.315 0.010 (3.28%)

High

$0.32

Low

$0.30

Trades

243

Turnover

$627,825

Volume

2,012,212
30 June 2023 at 4:10pm
Register to track IMM and receive email alerts.
Subject
IMM Ann: Application for quotation of securities - IMM

IMM Ann: Proposed issue of securities - IMM

IMM Ann: Notification regarding unquoted securities - IMM

IMM Ann: Results of Meeting

IMM Ann: Immutep AGM 2021 - CEO's Presentation

IMM Ann: Immutep AGM 2021 - Chairman's Address

IMM Ann: Phase II TACTI-002 trial recruitment successfully completed

IMM Ann: Change in substantial holding

IMM Ann: Immutep Global Webcast Slides to Discuss Clinical Results

IMM Ann: Change in substantial holding

IMM Ann: Immutep announces publication of SITC 2021 posters

IMM Ann: Chinese Patent Granted for Efti with PD-1 Pathway Inhibitors

IMM Article: Why big biotechs will have their eyes on Immutep

IMM Ann: Immutep announces publication of SITC 2021 abstracts

IMM Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC

IMM Ann: JobKeeper Payment Notice

IMM Ann: Immutep granted Chinese Patent for eftilagimod alpha

IMM Ann: Immutep receives EMA scientific advice for Phase 3 in MBC

IMM Ann: Immutep Quarterly Activities Report & Appendix 4C

IMM Ann: Notice of Annual General Meeting/Proxy Form

IMM Ann: Appendix 4G

IMM Ann: Annual Report to shareholders

IMM Ann: Annual Report filed on Form 20-F with SEC

IMM Ann: 2021 AGM & Key Dates

IMM Ann: Ceasing to be a substantial holder from AEF

IMM Ann: Change of Director's Interest Notice - Mr Chamberlain

IMM Ann: Change of Director's Interest Notice - Mr Meyers

IMM Ann: Immutep to present Phase II TACTI-002 data at SITC 2021

IMM Ann: Notification regarding unquoted securities - IMM

IMM Ann: Application for quotation of securities - IMM

IMM Ann: Immutep Receives A$3.4 million R&D French Tax Incentive

IMM Ann: Immutep to Present at Healthcare Investor Conferences

IMM Ann: Immutep Corporate Presentation

IMM Ann: Immutep to present final AIPAC Overall Survival data at SITC

IMM Ann: Recruitment of patients completed for Part B of TACTI-002

IMM Ann: Immutep's partner, EOC Pharma, expands efti trial pipeline

IMM Ann: Appendix 4E & 2021 Full Year Statutory Accounts

IMM Ann: Chinese patent granted for anti-LAG-3 antibody LAG525

IMM Ann: INSIGHT-003 investigator-initiated trial - 1st patient dosed

IMM Ann: Becoming a substantial holder

IMM Ann: Change in substantial holding

IMM Ann: Cleansing Notice

IMM Ann: Completion of Placement - Tranche 2

IMM Ann: Application for quotation of securities - IMM

IMM Ann: Change in substantial holding

IMM Ann: Proposed issue of securities - IMM

IMM Ann: Results of EGM

IMM Ann: Chairman's EGM Address

IMM Ann: 2021 EGM Presentation

IMM Ann: Application for quotation of securities - IMM

Register to track IMM and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMU
MSB
OPT
PAR
PYC
RAC
TLX